Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2022 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Occupational wheat contact dermatitis and treatment with omalizumab.
Mur Gimeno P, Martín Iglesias A, Lombardero Vega M, Bautista Martínez P, Ventura López P. Mur Gimeno P, et al. Among authors: ventura lopez p. J Investig Allergol Clin Immunol. 2013;23(4):287-8. J Investig Allergol Clin Immunol. 2013. PMID: 23964563 Free article. No abstract available.
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Redondo-Calvo FJ, Padín JF, Muñoz-Rodríguez JR, Serrano-Oviedo L, López-Juárez P, Porras Leal ML, González Gasca FJ, Rodríguez Martínez M, Pérez Serrano R, Sánchez Cadena A, Bejarano-Ramírez N, Muñoz Hornero C, Barberá Farré JR, Domínguez-Quesada I, Sepúlveda Berrocal MA, Villegas Fernández-Infantes MD, Manrique Romo MI, Parra Comino Á, Pérez-Ortiz JM, Gómez-Romero FJ; ATAC team. Redondo-Calvo FJ, et al. Eur J Clin Invest. 2022 Jun;52(6):e13776. doi: 10.1111/eci.13776. Epub 2022 Apr 5. Eur J Clin Invest. 2022. PMID: 35342931 Free PMC article. Clinical Trial.
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M; EXIT Study group of GETECCU. Gisbert JP, et al. Gut. 2025 Jan 22:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385. Online ahead of print. Gut. 2025. PMID: 39794921 Free article.